Eglumegad

Eglumegad is a conformationally constrained glutamate analogue that potently and selectively activates mGlu2/3 receptors, which function largely as presynaptic autoreceptors that suppress excessive glutamate release. This mechanism produced anxiolytic-like effects across numerous preclinical models without the sedation and dependence associated with benzodiazepines. Because its oral bioavailability was limited, the amino acid prodrug LY544344 was created to increase systemic exposure of eglumegad in humans ^[1].

In a human experimental panic study, one week of oral treatment with the prodrug reduced the number of panic symptoms and subjective anxiety provoked by intravenous cholecystokinin tetrapeptide, providing early evidence of anti-panic activity ^[1]. A subsequent eight-week randomized controlled trial in generalized anxiety disorder found that the higher prodrug dose produced significantly greater improvement in Hamilton Anxiety and Clinical Global Impression scores and higher response and remission rates than placebo, with good tolerability ^[2]. That trial was nonetheless discontinued early because of convulsions observed in preclinical studies, and the compound did not progress to registration ^[2]. Eglumegad remains one of the most influential probes of group II metabotropic glutamate signalling in anxiety.

Moderate clinical evidence in anxiety, development halted for safety

In human anxiety trials the prodrug LY544344 was well tolerated with no significant excess of treatment-emergent adverse events compared with placebo. The critical safety issue was the emergence of convulsions in preclinical species, which led to early trial termination for the class. As an investigational compound eglumegad is not approved and is used only in research.

LY354740 was synthesized at Eli Lilly in the 1990s as part of a program to create selective metabotropic glutamate agonists, and it quickly became the standard mGlu2/3 agonist tool compound. Human anxiety studies with the prodrug LY544344 in the mid-2000s demonstrated proof of concept in generalized anxiety disorder and experimental panic. Preclinical convulsion findings ended clinical development, but the molecule catalysed the broader mGlu2/3 field, including later work on pomaglumetad and mGlu2 positive allosteric modulators.

Eglumegad is regarded as a classic and highly cited tool compound in metabotropic glutamate research and as an early validation that group II agonism can relieve anxiety in humans. It is routinely referenced in reviews of glutamatergic anxiolytics and stress pharmacology. Although never marketed, its influence on the field is substantial and enduring.